349 related articles for article (PubMed ID: 34100149)
1. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
Ackaert O; McDougall D; Pérez-Ruixo C; Pérez-Ruixo JJ; Jezorwski J; Crauwels HM
AAPS J; 2021 Jun; 23(4):82. PubMed ID: 34100149
[TBL] [Abstract][Full Text] [Related]
2. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
Lathouwers E; Wong EY; Brown K; Baugh B; Ghys A; Jezorwski J; Mohsine EG; Van Landuyt E; Opsomer M; De Meyer S;
AIDS Res Hum Retroviruses; 2020 Jan; 36(1):48-57. PubMed ID: 31516033
[TBL] [Abstract][Full Text] [Related]
3. Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.
Huhn GD; Wilkin A; Mussini C; Spinner CD; Jezorwski J; El Ghazi M; Van Landuyt E; Lathouwers E; Brown K; Baugh B;
HIV Res Clin Pract; 2020 Dec; 21(6):151-167. PubMed ID: 33528318
[TBL] [Abstract][Full Text] [Related]
4. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study.
Rashbaum B; Spinner CD; McDonald C; Mussini C; Jezorwski J; Luo D; Van Landuyt E; Brown K; Wong EY
HIV Res Clin Pract; 2019 Feb; 20(1):24-33. PubMed ID: 31303147
[No Abstract] [Full Text] [Related]
5. Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
Lathouwers E; Weinsteiger S; Baugh B; Ghys A; Jezorwski J; Mohsine EG; Van Landuyt E; De Meyer S
J Med Virol; 2021 Jun; 93(6):3985-3990. PubMed ID: 33300183
[TBL] [Abstract][Full Text] [Related]
6. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
Orkin C; Molina JM; Negredo E; Arribas JR; Gathe J; Eron JJ; Van Landuyt E; Lathouwers E; Hufkens V; Petrovic R; Vanveggel S; Opsomer M;
Lancet HIV; 2018 Jan; 5(1):e23-e34. PubMed ID: 28993180
[TBL] [Abstract][Full Text] [Related]
8. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Huhn GD; Eron JJ; Girard PM; Orkin C; Molina JM; DeJesus E; Petrovic R; Luo D; Van Landuyt E; Lathouwers E; Nettles RE; Brown K; Wong EY
AIDS Res Ther; 2019 Aug; 16(1):23. PubMed ID: 31464642
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
Crauwels HM; Baugh B; Van Landuyt E; Vanveggel S; Hijzen A; Opsomer M
Clin Pharmacol Drug Dev; 2019 May; 8(4):480-491. PubMed ID: 30412360
[TBL] [Abstract][Full Text] [Related]
10. Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate.
Cevik M; Orkin C
Curr Opin HIV AIDS; 2018 Jul; 13(4):315-319. PubMed ID: 29528852
[TBL] [Abstract][Full Text] [Related]
11. Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD.
Dunn K; Baugh B; Bejou N; Luo D; Campbell J; Seyedkazemi S; Anderson D
J Int Assoc Provid AIDS Care; 2022; 21():23259582221088202. PubMed ID: 35466761
[TBL] [Abstract][Full Text] [Related]
12. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
Orkin C; Eron JJ; Rockstroh J; Podzamczer D; Esser S; Vandekerckhove L; Van Landuyt E; Lathouwers E; Hufkens V; Jezorwski J; Opsomer M;
AIDS; 2020 Apr; 34(5):707-718. PubMed ID: 31833849
[TBL] [Abstract][Full Text] [Related]
13. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Gaur AH; Kizito H; Prasitsueubsai W; Rakhmanina N; Rassool M; Chakraborty R; Batra J; Kosalaraksa P; Luesomboon W; Porter D; Shao Y; Myers M; Ting L; SenGupta D; Quirk E; Rhee MS
Lancet HIV; 2016 Dec; 3(12):e561-e568. PubMed ID: 27765666
[TBL] [Abstract][Full Text] [Related]
14. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Squillace N; Bozzi G; Colella E; Gori A; Bandera A
Drug Des Devel Ther; 2018; 12():3635-3643. PubMed ID: 30464395
[TBL] [Abstract][Full Text] [Related]
15. Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen.
Brown K; Thomas D; McKenney K; Reeder M; Simonson RB; Bicer C; Nettles RE; Crauwels H
Clin Pharmacol Drug Dev; 2019 May; 8(4):541-548. PubMed ID: 30508308
[TBL] [Abstract][Full Text] [Related]
16. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
Salama E; Hill L; Patel N; Best BM; Momper JD
J Acquir Immune Defic Syndr; 2021 Dec; 88(4):389-392. PubMed ID: 34285156
[TBL] [Abstract][Full Text] [Related]
18. Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged ≥6 to <12 years, using matching placebo tablets: A randomized study.
Van Hemelryck S; Van Landuyt E; Hufkens V; Vanveggel S
Antivir Ther; 2024 Apr; 29(2):13596535241248282. PubMed ID: 38725258
[TBL] [Abstract][Full Text] [Related]
19. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
[TBL] [Abstract][Full Text] [Related]
20. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
Eron JJ; Orkin C; Gallant J; Molina JM; Negredo E; Antinori A; Mills A; Reynes J; Van Landuyt E; Lathouwers E; Hufkens V; Jezorwski J; Vanveggel S; Opsomer M;
AIDS; 2018 Jul; 32(11):1431-1442. PubMed ID: 29683855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
